Is ALLR or PMN more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Promis Neurosciences N/A -237.99% -151.04%

Does the media favor ATRA or ALLR?

In the previous week, Allarity Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Allarity Therapeutics and 2 mentions for Atara Biotherapeutics. Allarity Therapeutics' average media sentiment score of 1.36 beat Atara Biotherapeutics' score of 0.93 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALLR or TELO?

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 693.34%. Given Allarity Therapeutics' higher possible upside, equities analysts plainly believe Allarity Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ALLR or TELO more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media prefer ALLR or TELO?

In the previous week, Allarity Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Allarity Therapeutics and 2 mentions for Telomir Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 1.36 beat Telomir Pharmaceuticals' score of 1.31 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ALLR or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allarity Therapeutics $320K 64.24 -$11.23M -$0.72 N/A China SXT Pharmaceuticals $1.74M 46.76 -$3.30M N/A N/A

Is ALLR or SXTC more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% China SXT Pharmaceuticals N/A N/A N/A

Does the media refer more to ALLR or SXTC?

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 1.36 beat China SXT Pharmaceuticals' score of 0.67 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALLR or BMEA more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Biomea Fusion N/A -265.37% -103.96%

Allarity Therapeutics (ALLR) Competitors

$1.29 -0.01 (-0.62%)

As of 10:57 AM Eastern

Compare

ALLR vs. PMN, ATRA, TELO, SXTC, and BMEA

Should you buy Allarity Therapeutics stock or one of its competitors? MarketBeat compares Allarity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allarity Therapeutics include Promis Neurosciences (PMN), Atara Biotherapeutics (ATRA), Telomir Pharmaceuticals (TELO), China SXT Pharmaceuticals (SXTC), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Allarity Therapeutics compare to Promis Neurosciences?

Allarity Therapeutics (NASDAQ:ALLR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Allarity Therapeutics had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Allarity Therapeutics and 2 mentions for Promis Neurosciences. Allarity Therapeutics' average media sentiment score of 1.36 beat Promis Neurosciences' score of 0.94 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Promis Neurosciences	Positive

Allarity Therapeutics' return on equity of -109.94% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Promis Neurosciences	N/A	-237.99%	-151.04%

Allarity Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 693.34%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 114.05%. Given Allarity Therapeutics' higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allarity Therapeutics has higher revenue and earnings than Promis Neurosciences. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	64.24	-$11.23M	-$0.72	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Allarity Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

Summary

Allarity Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Atara Biotherapeutics has higher revenue and earnings than Allarity Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.83	$32.69M	-$0.67	N/A
Allarity Therapeutics	$320K	64.24	-$11.23M	-$0.72	N/A

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Allarity Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Allarity Therapeutics and 2 mentions for Atara Biotherapeutics. Allarity Therapeutics' average media sentiment score of 1.36 beat Atara Biotherapeutics' score of 0.93 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential downside of 14.34%. Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 693.34%. Given Allarity Therapeutics' higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Atara Biotherapeutics and Allarity Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Allarity Therapeutics (NASDAQ:ALLR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Allarity Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Allarity Therapeutics and 2 mentions for Telomir Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 1.36 beat Telomir Pharmaceuticals' score of 1.31 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 693.34%. Given Allarity Therapeutics' higher possible upside, equities analysts plainly believe Allarity Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has lower revenue, but higher earnings than Allarity Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	64.24	-$11.23M	-$0.72	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Allarity Therapeutics' return on equity of -109.94% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Allarity Therapeutics beats Telomir Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Allarity Therapeutics compare to China SXT Pharmaceuticals?

Allarity Therapeutics (NASDAQ:ALLR) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Allarity Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

China SXT Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
China SXT Pharmaceuticals	N/A	N/A	N/A

China SXT Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	64.24	-$11.23M	-$0.72	N/A
China SXT Pharmaceuticals	$1.74M	46.76	-$3.30M	N/A	N/A

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 1.36 beat China SXT Pharmaceuticals' score of 0.67 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China SXT Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 693.34%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allarity Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Allarity Therapeutics and China SXT Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Allarity Therapeutics compare to Biomea Fusion?

Allarity Therapeutics (NASDAQ:ALLR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Allarity Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.89 beat Allarity Therapeutics' score of 1.36 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Biomea Fusion	Very Positive

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Allarity Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Allarity Therapeutics currently has a consensus target price of $10.25, indicating a potential upside of 693.34%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 488.24%. Given Allarity Therapeutics' higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Allarity Therapeutics' return on equity of -109.94% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Biomea Fusion	N/A	-265.37%	-103.96%

Allarity Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	64.24	-$11.23M	-$0.72	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Allarity Therapeutics beats Biomea Fusion on 8 of the 14 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.60M	$3.64B	$6.80B	$12.48B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-1.80	20.98	25.72	24.65
Price / Sales	64.24	344.19	545.41	102.66
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	2.12	8.74	10.94	6.52
Net Income	-$11.23M	$23.81M	$3.57B	$336.61M
7 Day Performance	-2.12%	3.42%	2.21%	1.24%
1 Month Performance	-21.22%	1.43%	0.55%	0.28%
1 Year Performance	27.92%	69.73%	36.44%	30.62%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	2.3059 of 5 stars	$1.29 -0.6%	$10.25 +693.3%	+30.0%	$20.60M	$320K	N/A	10	News Coverage Positive News
PMN Promis Neurosciences	3.5562 of 5 stars	$10.16 +1.1%	$26.50 +160.8%	-10.5%	$90.12M	N/A	N/A	5	Analyst Forecast
ATRA Atara Biotherapeutics	0.9725 of 5 stars	$9.62 -3.4%	$9.50 -1.2%	+40.3%	$89.74M	$120.77M	N/A	330	Analyst Upgrade
TELO Telomir Pharmaceuticals	0.6441 of 5 stars	$1.28 -0.8%	N/A	-18.3%	$88.72M	N/A	N/A	1	Positive News
SXTC China SXT Pharmaceuticals	0.5047 of 5 stars	$2.32 -1.3%	N/A	-99.2%	$88.67M	$1.54M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. PMN, ATRA, TELO, SXTC, and BMEA

How does Allarity Therapeutics compare to Promis Neurosciences?

Summary

How does Allarity Therapeutics compare to Atara Biotherapeutics?

Summary

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Allarity Therapeutics compare to China SXT Pharmaceuticals?

Summary

How does Allarity Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. PMN, ATRA, TELO, SXTC, and BMEA

How does Allarity Therapeutics compare to Promis Neurosciences?

Does the media prefer ALLR or PMN?

Is ALLR or PMN more profitable?

Do analysts recommend ALLR or PMN?

Do institutionals and insiders hold more shares of ALLR or PMN?

Which has higher valuation and earnings, ALLR or PMN?

Which has more volatility and risk, ALLR or PMN?

Summary

How does Allarity Therapeutics compare to Atara Biotherapeutics?

Which has better valuation and earnings, ATRA or ALLR?

Which has more volatility & risk, ATRA or ALLR?

Do insiders and institutionals have more ownership in ATRA or ALLR?

Does the media favor ATRA or ALLR?

Is ATRA or ALLR more profitable?

Do analysts recommend ATRA or ALLR?

Summary

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Does the media prefer ALLR or TELO?

Which has more risk and volatility, ALLR or TELO?

Do analysts prefer ALLR or TELO?

Which has better valuation & earnings, ALLR or TELO?

Is ALLR or TELO more profitable?

Do institutionals and insiders believe in ALLR or TELO?

Summary

How does Allarity Therapeutics compare to China SXT Pharmaceuticals?

Which has more risk and volatility, ALLR or SXTC?

Do insiders and institutionals hold more shares of ALLR or SXTC?

Is ALLR or SXTC more profitable?

Which has higher valuation and earnings, ALLR or SXTC?

Does the media refer more to ALLR or SXTC?

Do analysts rate ALLR or SXTC?

Summary

How does Allarity Therapeutics compare to Biomea Fusion?

Does the media prefer ALLR or BMEA?

Do insiders and institutionals hold more shares of ALLR or BMEA?

Which has more volatility and risk, ALLR or BMEA?

Do analysts recommend ALLR or BMEA?

Is ALLR or BMEA more profitable?

Which has higher valuation and earnings, ALLR or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools